glutathione peroxidase monoclonal antibody Anti-Glutathione 4 [EPNCIR144] (ab125066) Suitable for IHC The Selenoprotein Glutathione Peroxidase 4:

rhGH was first developed by the American biotechnology company Genentech in 1981

It is synthesized primarily in the liver, though individual cells can help regulate their own intracellular glutathione levels based on metabolic need

doi: 10.1016/j.nano.2008.05.005

The enhanced proliferative response of vascular smooth muscle cells was shown to be caused by the inactivation of the SH2 domain-containing protein tyrosine phosphatase 2 (SHP-2 phosphatase) by glutathionylation to allow for the sustained phosphorylation and activation of the tyrosine kinase ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase)

Results: Improvements are often seen within 3-7 days, with the full effect taking about 2 weeks